Printer Friendly

Sanofi-Aventis SA.

And the FDA sent a warning letter to Sanofi-Aventis SA accusing the French drugmaker of distributing misleading promotional material on its Uroxatral treatment for urinary problems caused by an enlarged prostate. At issue is a promotional card that touts the benefits of Uroxatral on the front, but only lists proper use of the medicine, risks associated with the drug, and those who should not be taking it, on the back. While noting that the use and risk information is included, the FDA warning letter said the so-called tent card is designed to be adhered to a flat surface, such as a pharmacy counter, "and as a practical matter, viewers of the front side of the card are unlikely to be able to view the back side of the card once it is stuck in place."

COPYRIGHT 2009 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2009 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:FDA ROUNDUP
Publication:MondayMorning
Article Type:Brief article
Date:Nov 2, 2009
Words:135
Previous Article:In other action, the FDA confirmed that Shire Plc's attention-deficit hyperactivity drug was entitled to five years of exclusivity.
Next Article:Weekly stock performance (as of October 30, 2009).
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters